{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:19:16Z","timestamp":1787818756138,"version":"build-2784847793"},"reference-count":60,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Despite receiving appropriate antiseizure medications (ASMs), a relevant percentage of neuropsychiatric patients do not benefit from this approach, and one reason is subtherapeutic ASMs plasma concentration (C(p)) due to improper drug adherence, interindividual pharmacokinetic differences, or metabolic interactions among different drugs. For these reasons, therapeutic drug monitoring (TDM) by measuring ASMs C(p) is an effective tool that improves pharmacological therapies in clinical practice. Based on these premises, in the present real-world study, we analyzed the C(p) of the most used ASMs in diverse medical conditions, which were assayed during the years 2018\u20132022 at the University Hospital of Pisa, including about 24,000 samples. This population was largely heterogeneous, and our database did not contain clinical information about the patients. The most used ASMs were Valproate (VPA: 54.5%) and Levetiracetam (LEV: 18.6%), followed by Oxcarbazepine (OxCBZ: 8.3%) and Carbamazepine (CBZ: 7.2%), whereas the associations LEV\/VPA, Ethosuximide (ESM)\/VPA, and CBZ\/VPA were the most frequently proposed. In about 2\/3 of assays, ASMs C(p) was in range, except for VPA, which was underdosed in almost half of the samples. Importantly, toxic levels of ASMs C(p) were found very rarely. For VPA, there was a decrease of mean C(p) across ages, from adolescents to older patients, while the C(p) of LEV, CBZ, OxCBZ, and Topiramate (TPM) showed a slight tendency to increase. When we compared females and males, we found that for VPA, the average age was higher for females, whereas women taking Lamotrigine (LTG) and OxCBZ were younger than men. Then, comparing ASMs used in neurologic and psychiatric disorders, based on the request form, it emerged that the mean C(p) of CBZ, OxCBZ, and LTG on samples collected in the Psychiatric Unit was lower compared to the Neurology and Child Neuropsychiatry Units. Finally, the ASMs subjected to multiple dosing starting from an initial subtherapeutic C(p) increased their level at different time points within a year, reaching the reference range for some of them. In conclusion, the present study suggests that TDM is widely applied to monitor ASMs C(p), finding many of them within the reference range, as a demonstration of its utility in clinical practice.<\/jats:p>","DOI":"10.3390\/ph16070945","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:17:46Z","timestamp":1688087866000},"page":"945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A 5-Year Study of Antiseizure Medications (ASMs) Monitoring in Patients with Neuropsychiatric Disorders in an Italian Clinical Center"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-4615","authenticated-orcid":false,"given":"Letizia","family":"Biso","sequence":"first","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-4947","authenticated-orcid":false,"given":"Marco","family":"Carli","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Kolachalam","sequence":"additional","affiliation":[{"name":"Aseptic Pharmacy, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London W6 8RF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Monticelli","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-6183","authenticated-orcid":false,"given":"Antonello","family":"di Paolo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-8128","authenticated-orcid":false,"given":"Filippo Sean","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9141","authenticated-orcid":false,"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarselli","sequence":"additional","affiliation":[{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/YIC.0b013e32833c4ceb","article-title":"Identification of clinical factors associated with resistance to antidepressants in bipolar depression: Results from an European Multicentre Study","volume":"25","author":"Mendlewicz","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_3","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: A systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_6","unstructured":"Kolachalam, S., Aringhieri, S., and Scarselli, M. (2020). Brain and Heart Dynamics, Springer."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","article-title":"Why are antiepileptic drugs used for nonepileptic conditions?","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1468-2982.1997.1702093.x","article-title":"Possible mechanisms of valproate in migraine prophylaxis","volume":"17","author":"Cutrer","year":"1997","journal-title":"Cephalalgia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"216125","DOI":"10.1016\/j.canlet.2023.216125","article-title":"Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?","volume":"560","author":"Natale","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"56126","DOI":"10.2174\/1570159X2104230307123319","article-title":"Lithium and Valproic Acid in Bipolar Disorders and Beyond","volume":"21","author":"Scarselli","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.58.11.1652","article-title":"A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis","volume":"58","author":"Freitag","year":"2002","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.4088\/JCP.15cr10147","article-title":"Valproate Intoxication in a Patient With Blood Valproate Levels Within Therapeutic Range","volume":"78","author":"Smits","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/YIC.0000000000000394","article-title":"Oxcarbazepine versus sodium valproate in treatment of acute mania: A double-blind randomized clinical trial","volume":"37","author":"Talaei","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0035-1559635","article-title":"Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine","volume":"48","author":"Unholzer","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"ref_16","first-page":"CD009183","article-title":"Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults","volume":"2011","author":"Gill","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","first-page":"CD011412","article-title":"Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure Medications for Adults With Epilepsy: A Review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"ref_19","unstructured":"EMA (2018). PRAC recommends new measures to avoid valproate exposure in pregnancy. Medicines, 44, 1\u20134."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0140-6736(97)06250-8","article-title":"Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India","volume":"351","author":"Pal","year":"1998","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.329.7476.1199","article-title":"Revisiting phenobarbital for epilepsy","volume":"329","author":"Kale","year":"2004","journal-title":"Br. Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e000377","DOI":"10.1136\/bmjno-2022-000377","article-title":"Efficacy of 48 h dose of phenytoin in prevention of early post-traumatic seizure","volume":"5","author":"Oyemolade","year":"2023","journal-title":"BMJ Neurol. Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.seizure.2017.07.017","article-title":"Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison","volume":"51","author":"Zhu","year":"2017","journal-title":"Seizure"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.9758\/cpn.2022.20.3.403","article-title":"Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors","volume":"20","author":"Crapanzano","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1528-1157.2000.tb00144.x","article-title":"A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy","volume":"41","author":"Jannuzzi","year":"2000","journal-title":"Epilepsia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/CPJ.0000000000000722","article-title":"Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review","volume":"10","author":"Guadagno","year":"2020","journal-title":"Neurol. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"734689","DOI":"10.1155\/2014\/734689","article-title":"Identification and Prevention of Antiepileptic Drug Noncompliance: The Collaborative Use of State-Supplied Pharmaceutical Data","volume":"2014","author":"Hodges","year":"2014","journal-title":"ISRN Pediatr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pennazio, F., Brasso, C., Villari, V., and Rocca, P. (2022). Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122674"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.annepidem.2011.08.002","article-title":"Use of antiepileptic medications in pregnancy in relation to risks of birth defects","volume":"21","author":"Werler","year":"2011","journal-title":"Ann. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5001\/omj.2010.5","article-title":"Correlation between Serum Level of Antiepileptic Drugs and their Side Effects","volume":"25","author":"Hussein","year":"2010","journal-title":"Oman Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","article-title":"Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations","volume":"31","author":"Riva","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fuhr, L.M., Marok, F.Z., Hanke, N., Selzer, D., and Lehr, T. (2021). Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020270"},{"key":"ref_35","first-page":"CD003032","article-title":"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents","volume":"2","author":"Brigo","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/HRP.0000000000000292","article-title":"Long-Term Treatment of Bipolar Disorder with Valproate: Updated Systematic Review and Meta-analyses","volume":"29","author":"Yee","year":"2021","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.110.067363","article-title":"Regulation of M\u2083 muscarinic receptor expression and function by transmembrane protein 147","volume":"79","author":"Rosemond","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Carli, M., Risaliti, E., Francomano, M., Kolachalam, S., Longoni, B., Bocci, G., Maggio, R., and Scarselli, M. (2022). A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010105"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Linde, M., Mulleners, W.M., Chronicle, E.P., and McCrory, D.C. (2013). Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev., CD010611.","DOI":"10.1002\/14651858.CD010611"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17562864211037430","DOI":"10.1177\/17562864211037430","article-title":"Efficacy and tolerability of antiseizure drugs","volume":"14","author":"Hakami","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WCO.0000000000000076","article-title":"Patients\u2019 safety in the epilepsy monitoring unit: Time for revising practices","volume":"27","author":"Rheims","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejpn.2007.09.004","article-title":"Add-on levetiracetam in children and adolescents with refractory epilepsy: Results of an open-label multi-centre study","volume":"12","author":"Callenbach","year":"2008","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"ref_45","first-page":"248","article-title":"Levetiracetam in children, adolescents and young adults with intractable epilepsy: Efficacy, tolerability and effect on electroencephalogram--a pilot study","volume":"17","author":"Feldman","year":"2013","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: A meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14656566.2020.1829594","article-title":"Pharmacological treatment of focal epilepsy in adults: An evidence based approach","volume":"22","author":"Mula","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11882-018-0778-6","article-title":"Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management","volume":"18","author":"Mustafa","year":"2018","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yebeh.2017.07.001","article-title":"Adherence to antiepileptic drugs in children and adolescents: A retrospective study in primary care settings in Germany","volume":"75","author":"Jacob","year":"2017","journal-title":"Epilepsy Behav."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/dmcn.12942","article-title":"Adherence to antiepileptic drugs in children with epilepsy in a Scottish population cohort","volume":"58","author":"Shetty","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"845032","DOI":"10.3389\/fpubh.2022.845032","article-title":"The Influence of Parents on Medication Adherence of Their Children in China: A Cross-Sectional Online Investigation Based on Health Belief Model","volume":"10","author":"Ge","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/CIA.S3785","article-title":"Review of topiramate for the treatment of epilepsy in elderly patients","volume":"5","author":"Sommer","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1533317508325095","article-title":"Levetiracetam: A practical option for seizure management in elderly patients with cognitive impairment","volume":"25","author":"Lippa","year":"2010","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: An observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Grunze, A., Amann, B.L., and Grunze, H. (2021). Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder. Medicina, 57.","DOI":"10.3390\/medicina57050433"},{"key":"ref_60","first-page":"326","article-title":"Pharmacokinetic monitoring of antiepileptic drugs","volume":"35","author":"Aldaz","year":"2011","journal-title":"Farm. Hosp. Organo Of. Expr. Cient. Soc. Esp. Farm. Hosp."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:51Z","timestamp":1760126631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16070945"],"URL":"https:\/\/doi.org\/10.3390\/ph16070945","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}